IMPACT OF COVID-19 INFECTION IN CHRONIC RHEUMATIC DISEASES TREATED WITH IMMUNOSUPPRESSANT DRUGS (Q4201962)
Jump to navigation
Jump to search
Project Q4201962 in Italy
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | IMPACT OF COVID-19 INFECTION IN CHRONIC RHEUMATIC DISEASES TREATED WITH IMMUNOSUPPRESSANT DRUGS |
Project Q4201962 in Italy |
Statements
180,508.78 Euro
0 references
361,017.57 Euro
0 references
50.0 percent
0 references
DIA.PRO DIAGNOSTIC BIOPROBES S.R.L.
0 references
CONSORZIO ITALBIOTEC
0 references
FONDAZIONE ISTITUTO NAZIONALE GENETICA MOLECOLARE - INGM
0 references
AZIENDA SOCIO SANITARIA TERRITORIALE (ASST) CENTRO SPECIALISTICO ORTOPEDICO TRAUMATOLOGICO GAETANO PINI-CTO
0 references
LA PANDEMIA COVID-19 STA PONENDO GRANDE PRESSIONE SUL SSN. L ENORME AFFLUENZA DI PAZIENTI UNITO ALLA MANCANZA DI TERAPIE SPECIFICHE PER IL SARS-COV-2 PORTA AD UNA NOTEVOLE GESTIONE DEI PAZIENTI OSPEDALIZZATI. DATA LA NECESSITà DI TERAPIE EFFICACI CONTRO IL COVID-19 LA RIALLOCAZIONE DI FARMACI GIà UTILIZZATI IN CLINICA Ê ALTAMENTE AUSPICABILE.L IPOTESI ALLA BASE DEL PROGETTO Ê CHE TERAPIE DI TIPO IMMUNOSOPPRESSIVO POSSANO MITIGARE LA SINDROME DA RILASCIO CITOCHINICO E L IPER-ATTIVAZIONE DEL SISTEMA IMMUNITARIO RESPONSABILE DEL DANNO TISSUTALE CHE PROVOCA FORME GRAVI DI COVID-19. I PAZIENTI AFFETTI DA PATOLOGIE REUMATICHE AUTOIMMUNI, IN PARTICOLARE I PAZIENTI CON ARTRITI CRONICHE COME ARTRITE REUMATOIDE (AR) E SPONDILOARTRITI SIERONEGATIVE (SPA) RAPPRESENTANO UN IMPORTANTE PROBLEMA NEL CORSO DELL'ATTUALE PANDEMIA. INFATTI PRESENTANO MEDIAMENTE UN MEDIO-ELEVATO GRADO DI DISABILITà , PRESENTANO COMORBIDITà IN PIù DEL 60% DEI CASI E NECESSITANO DI UN TRATTAMENTO IMMUNOSOPPRESSIVO I (Italian)
0 references
THE COVID-19 PANDEMIC IS PUTTING GREAT PRESSURE ON THE NHS. THE HUGE TURNOUT OF UK PATIENTS TO THE LACK OF SPECIFIC SARS-COV-2 THERAPIES LEADS TO A CONSIDERABLE MANAGEMENT OF HOSPITALISED PATIENTS. DUE TO THE NEED FOR EFFECTIVE THERAPIES AGAINST COVID-19, THE REALLOCATION OF DRUGS ALREADY USED IN THE CLINIC IS HIGHLY AUSPICABLE.THE HYPOTHESIS BEHIND THE PROJECT IS THAT IMMUNOSUPPRESSIVE THERAPIES CAN MITIGATE THE RELEASE SYNDROME CITOCHINICO AND THE HYPER-ACTIVATION OF THE IMMUNE SYSTEM RESPONSIBLE FOR TISSUE DAMAGE THAT CAUSES SEVERE FORMS OF COVID-19. PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES, IN PARTICULAR PATIENTS WITH CHRONIC ARTHRITIS SUCH AS RHEUMATOID ARTHRITIS (AR) AND SERONEGATIVE SPONDYLOARTHRITIS (SPA) ARE A MAJOR PROBLEM DURING THE CURRENT PANDEMIC. IN FACT, THEY HAVE AN AVERAGE TO HIGH DEGREE OF DISABILITY, PRESENT COMORBIDITIES IN MORE THAN 60 % OF CASES AND REQUIRE IMMUNOSUPPRESSIVE TREATMENT. (English)
1 February 2022
0 references
LA PANDÉMIE DE COVID-19 EXERCE UNE FORTE PRESSION SUR LE NHS. LA FORTE PARTICIPATION DES PATIENTS BRITANNIQUES À L’ABSENCE DE THÉRAPIES SPÉCIFIQUES AU SRAS-COV-2 CONDUIT À UNE PRISE EN CHARGE CONSIDÉRABLE DES PATIENTS HOSPITALISÉS. EN RAISON DE LA NÉCESSITÉ DE THÉRAPIES EFFICACES CONTRE LA COVID-19, LA RÉALLOCATION DES MÉDICAMENTS DÉJÀ UTILISÉS DANS LA CLINIQUE EST HAUTEMENT AUSPICABLE.L’HYPOTHÈSE DERRIÈRE LE PROJET EST QUE LES THÉRAPIES IMMUNOSUPPRESSIVES PEUVENT ATTÉNUER LE SYNDROME DE LIBÉRATION CITOCHINICO ET L’HYPER-ACTIVATION DU SYSTÈME IMMUNITAIRE RESPONSABLE DES LÉSIONS TISSULAIRES QUI CAUSENT DES FORMES GRAVES DE COVID-19. LES PATIENTS ATTEINTS DE MALADIES RHUMATISMALES AUTO-IMMUNES, EN PARTICULIER LES PATIENTS ATTEINTS D’ARTHRITE CHRONIQUE, COMME LA POLYARTHRITE RHUMATOÏDE (AR) ET LA SPONDYLOARTHRITE SÉRONÉGATIVE (SPA), CONSTITUENT UN PROBLÈME MAJEUR PENDANT LA PANDÉMIE ACTUELLE. EN FAIT, ILS ONT UN DEGRÉ MOYEN À ÉLEVÉ D’INCAPACITÉ, PRÉSENTENT DES COMORBIDITÉS DANS PLUS DE 60 % DES CAS ET NÉCESSITENT UN TRAITEMENT IMMUNOSUPPRESSEUR. (French)
2 February 2022
0 references
MILANO
0 references
SESTO SAN GIOVANNI
0 references